Filing Details

Accession Number:
0001855763-24-000012
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-01 12:25:52
Reporting Period:
2024-07-31
Accepted Time:
2024-08-01 12:25:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1348362 Lexaria Bioscience Corp. LEXX Pharmaceutical Preparations (2834) 202000871
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1855763 Vanessa Carle 100 - 740 Mccurdy Road
Kelowna A1 V1X 2P7
Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Disposition 2024-07-31 2,567 $4.00 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Shares 2,567 Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Shares Warrants $36.00 2019-11-13 2024-11-13 67 67 Direct
Common Shares Stock Options $3.00 2021-04-26 2026-04-26 12,500 12,567 Direct
Common Shares Stock Options $3.00 2021-06-08 2026-06-08 5,000 17,567 Direct
Common Shares Stock Options $3.00 2021-09-01 2026-09-01 10,000 27,567 Direct
Common Shares Stock Options $2.91 2022-08-29 2027-08-29 12,500 40,067 Direct
Common Shares Stock Options $1.15 2023-10-26 2028-10-26 10,000 50,067 Direct
Common Shares Stock Options $2.36 2024-04-26 2029-04-26 10,000 60,067 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2024-11-13 67 67 Direct
2026-04-26 12,500 12,567 Direct
2026-06-08 5,000 17,567 Direct
2026-09-01 10,000 27,567 Direct
2027-08-29 12,500 40,067 Direct
2028-10-26 10,000 50,067 Direct
2029-04-26 10,000 60,067 Direct
Footnotes
  1. Repriced from $5.31 pursuant to shareholder approval received May 9,2023
  2. Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
  3. Repriced from $6.23 pursuant to shareholder approval received May 9, 2023